Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Wang, Yiping ^a   Pan, Tao ^a   Wang, Qiong ^b   Guo, Zhen ^a  

^a SICHUAN UNIVERSITY   (China)

^b Third People's Hospital   (China)

Author keywords

Drug administration schedule; Gastric acid *secretion ; Histamine H2 antagonists *administration dosage ; Humans; Randomized controlled trials as topic

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EVENING DOSAGE; GASTROESOPHAGEAL REFLUX; HUMAN; META ANALYSIS; MORNING DOSAGE; PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; STOMACH PH; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77950125139     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004275.pub3     Document Type: Review

References (44)

1. Bing 2005 {published data only} Bing W, Shaoyong X, Yong D, Jun S. The relationship and clinical meaning of nocturnal gastric acid breakthrough and acid exposure of esophagus. New Chinese Medicine 2005;36(2):79-80.
2. Cong 2004 {published data only} Cong L, You J, Ruxin L, Chunmeng J, Miaona J, Yujie J. Clinical investigation into nocturnal acid breakthrough in patients with duodenal ulcer. Chinese Journal of Practical Internal Medicine. 2004;24(12):725-727.
3. Cong 2004b {published data only} Cong L, You J, Miaona J, Shanhong Z, Yanjin L, Chunmeng J, Yujie J. Clinical study of nocturnal acid breakthrough in old patients with duonenal ulcer. World Chinese Journal of Digestology 2004;12(10):2514-2517.
4. Hong 2002 {published data only} Hong W, Yuyuan L, Yuqiang L, Weihong S, Shoujun D. Treatment for nocturnal acid breakthrough. New Chinese Medicine 2002;33(9):539-541.
5. Janiak 2007 {published data only} Janiak P, Thumshirn M, Menne D, Fox M, Halim S, Fried M at al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis-a randomized controlled, cross-over trial. Alimentary Pharmacology and Therapeutics 2007;26(9): 1259-65.
6. Jun 2005 {published data only} Jun S, Xiaoping X, Hanhua X, Xiaohua H. A Controlled Study of Famotidine and omeprazole on daytime and nocturnal gastric acid breakthrough in duodenal ulcer. Chinese Journal of Clinical Gastroenterology 2005;17(5):212-213.
7. Khoury 1999 {published data only} Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily does of omeprazole to suppress nocturnal gastric pH. Alimentary Pharmacology and Therapeutics 1999;13(5):675-678.
8. Peghini 1998b {published data only} Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115(6):1335-1339.
9. Brummer 1996 {published data only} Brummer RJM, Stockbrugger RW. Effect of nizatidine 300mg at night and omeprazole 20mg in the morning on 24-hour intragastric pH bacterial overgrowth in patients with acute duodenal ulcer. Digestive Diseases and Sciences 1996;41(10):2048- 2054.
10. Chunli 2005 {published data only} Chunli H, You J, Zhaohui W, Chunmeng J. Rabeprazole and Omeprazole treat for duonenal ulcers. Journal of Postgraduate Medicine 2005;28(3):31-34.
11. Fackler 2002 {published data only} Fackler WK, Ours TM, Vaczi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122(3):625-632.
12. Fackler 2000 {published data only} Fackler WK, Vaezi MF, Ours TM, Richter JE. Nocturnal acid breakthrough and H2RAs: Another viewpoint. American Journal of Gastroenterology 2000;95(9):2419.
13. JianQiang 2005 {published data only} JianQiang G, Shutian Z, Bin L, Qingling G, Weihua X, Hua L, Hongbo W. Comparision of inhibitive effect on gastric acid between single dose rabeprazole and esomeprazole in healthy volunteers. Chinese Journal of Clinical Pharmacy 2005;14(1):1-5.
14. Judmaier 1994 {published data only} Judmaier G, Koelz HR. Comparision of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Alimentary Pharmacology & Therapeutics 1994;8(1):81-6.
15. Katsube 2000 {published data only} Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, et al.Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Alimentary Pharmacology and Therapeutics 2000;14(8):1049-1056.
16. Keshang 2005 {published data only} Keshang L, Wenhu C, Guanghuan C. Treatment for nocturnal heartburn of PPI ineffective nonerosive reflux disease. Journal of Postgraduate Medicine 2005;28(6):25-27.
17. Pfefferkorn 2006 {published data only} Pfefferkorn M, Croffie J, Gupta S, Molleston J, Eckert G, Corkins M, Fitzgerald J. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology & Nutrition 2006;42(2):160-165.
18. Robinson 2002 {published data only} Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, et al.Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Digestive Disease & Sciences 2002;47(2):265-73.
19. Shimatani 2006 {published data only} Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, et al.Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Digestive Diseases & Sciences. 2006;51(1):114-20.
20. Shuwen 2000 {published data only} Shuwen X, Philip O, Katz JA, Castell DO. Bedtime H2 blockers control nocturnal gastric acid breakthrough in GERD patients. Gastroenterology 2000;118(4):A22.
21. Sugimoto 2005 {published data only} Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Hishida A, et al.Comparision of an increased dosage regimen rabeprazole versus a concomitent dosage regimen of Famotidine with rebeprazole for nocturnal acid inhibition in relation to cytochrome P4502C19 genotypes. Clinical Pharmacology & Therapeutics 2005;77(4):302-311.
22. Tina 2003 {published data only} Tina M, Ours RN, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with oesophageal acid exposure. American Journal of Gastroenterology 2003;98(3):545-550.
23. Tutuian 2002 {published data only} Tutuian R, Katz PO, Ahmed F, Korn S, Castell DO. Over-the-counter H2-receptor antagonist do not compromise intragastric PH control with proton pump inhibitors. Alimentary Pharmacology and Therapeutics 2002;16(3):473-477.
24. Van Zyl 2000 {published data only} Van Zyl JH, De K Grundling H, Van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, et al.Efficacy and tolerability of 20mg pantoprazole versus 300mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind,parallel,and multicentre study. European Journal of Gastroenterology & Hepatology. 2000;12(2):197-202.
25. Warrington 2007 {published data only} Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Alimentary Pharmacology and Therapeutics. 2007;25(4):511-517.
26. Xiaohui 2005 {published data only} Xiaohui L. Omeprazole combine ranitidine control for nocturnal gastric acid. Journal of Practical Training of Medicine 2005;33(2):102-103.
27. Xue 2001 {published data only} Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Alimentary Pharmacology and Therapeutics 2001;15(9):1351-1356.
28. Bate 1990 Bate CM, Keeling PW, O'Morain C, Wilkinson SP, Foster DN, Mountford RA, et al.Comparison of omeprazole and cimetidine in reflux esophagitis: symptomatic, endoscopic, and histologic evaluations. Gut 1990;31(9):968-972.
29. Bell 1992 Bell NJ, Burget D, Howden CW, WilkinsonJ, Hunt RH. Appropriate acidsuppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl. 1):59-67.
30. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
31. Fitzgerald 1996 Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's oesophagus: an ex vivo proliferation and differentiation model. Journal of Clinical Investigation 1996;98(9):2120-2128.
32. Furuta 2001 Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of highdose lansoprazole on intragastric PH in subjects who are homozygous extensive metabolizers of cytochrome P450C19. Clinical Pharmacology and Therapeutics 2001;70(5):484-492.
33. Higgins 2008 Higgins, JPT, Green, S. (Eds.). Designing search strategies. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. updated 2008. Vol. Section 6.4, The Cochrane Collaboration, 10 April 2008.
34. Hongo 1992 Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Digestive Diseases and Sciences 1992;37(6):882- 890.
35. Katz 1998 Katz PO, Anderson C, Khoury R, Castell DO. Gastric-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Alimentary Pharmacology and Therapeutics 1998;12(12):1231-1234.
36. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11): 982-989.
37. Maton 1991 Maton PN. Omeprazole. New England Journal of Medicine 1991;324(14):965-975.
38. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998;352:609-613.
39. Ouatu-Lascar 1999 Ouatu-Lascar R, Fitzgerald R, Triadafilopoulos G. Differentiation and proliferation in Barrett's oesophagus and the effects of acid suppression. Gastroenterology 1999;117(2):327-335.
40. Peghini 1998a Peghini PL, Katz PO, Bracy NA, Castell DA. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. American Journal of Gastroenterology 1998;93(5):763- 767.
41. Peters 1999 Peters FTM, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45(4):489-494.
42. Schulz 1995 Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. JAMA 1995;273(5):408-412.
43. Shirai 2002 Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, et al.Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime night-time in different CYP2C19 genotype groups. Alimentary Pharmacology and Therapeutics 2002;16(4):837-846.
44. Van Herwaarden 2000 Van Herwaarden MA, Samson M, Smout AJ. Helicobacter pylori eradication increases nocturnal acid breakthrough. Alimentary Pharmacology and Therapeutics 2000;14(7):961-962.